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ABSTRACT
The Nuclear Factor-kappa B (NF-κB) family of transcription factors plays a 
key role in cancer pathogenesis due to the ability to promote cellular proliferation 
and survival, to induce resistance to chemotherapy and to mediate invasion and 
metastasis. NF-κB is recruited through different mechanisms involving either 
canonical (RelA/p50) or non-canonical pathways (RelB/p50 or RelB/p52), which 
transduce the signals originated from growth-factors, cytokines, oncogenic stress 
and DNA damage, bacterial and viral products or other stimuli. The pharmacological 
inhibition of the NF-κB pathway has clearly been associated with significant clinical 
activity in different cancers. Almost 20 years ago, NF-κB was described as an essential 
modulator of BCR-ABL signaling in Chronic Myeloid Leukemia and Philadelphia-
positive Acute Lymphoblastic Leukemia. This review summarizes the role of NF-κB 
in BCR-ABL-mediated leukemogenesis and provides new insights on the long lasting 
BCR-ABL/NF-κB connection.
INTRODUCTION
The Philadelphia chromosome (Ph+) refers to 
the translocation t(9;22) and is the genetic hallmark 
of chronic myeloid leukemia (CML) and of about one 
third of acute lymphoblastic leukemias (ALL) [1–5]. Ph+ 
chromosome codes for the BCR-ABL chimeric protein 
which is characterized by the constitutive activation of 
the tyrosine kinase ABL [6–9]. The generation of the 
p210-BCR-ABL isoform is responsible for the CML 
phenotype, while the shorter p190-BCR-ABL isoform 
leads to the development of Ph+ ALL [10]. However, the 
presence of p210-BCR-ABL isoform is not restricted to 
CML, as it is found in 10% to 20% of adults and in a small 
percentage of children with ALL[11–13]. Although BCR-
ABL tyrosine kinase inhibitors (TKIs) have undoubtedly 
revolutionized the therapy of Ph+ leukemias [14,15], both 
CML and ALL are not completely eradicated by BCR-
ABL inhibition, as extensively reviewed elsewhere [16–
20]. In particular, the major unmet clinical needs in the 
field of Ph+ leukemias are represented by: i) the incomplete 
eradication of CML chronic phase, ii) the need for a better 
control of CML blast phase [21] and iii) the improvement 
of TKIs efficacy in Ph+ ALL [22]. Therefore, the molecular 
dissection of BCR-ABL signaling network is advisable 
to identify the signaling axes which are essential for 
the maintenance of Ph+ leukemias and whose inhibition 
allows to achieve synthetic lethality together with BCR-
ABL TKIs. Synthetic lethal therapies, designed to target 
those synthetic lethal partners of genetic aberrations 
found in cancers, allow to selectively target cancer cells 
while sparing normal cells, as extensively reviewed 
[23]. In accordance with this notion, tandem inhibition 
of NF-κB signaling proteins together with potential 
synergistic pathways has always appeared as an attractive 
strategy. The Nuclear Factor-kappaB (NF-κB) family of 
transcription factors was originally investigated in the 
immune system due to its ability to regulate the expression 
of cytokines and effector enzymes, especially in response 
to the activation of several receptors involved in immunity, 
including T and B-cell receptors [24, 25]. Furthermore, 
the NF-κB pathway has been linked to the regulation of 
Oncotarget2www.impactjournals.com/oncotarget
several processes involved in tumorigenesis [26,27]. These 
include proliferative signaling [28], cell death evasion 
[29, 30] and resistance to chemotherapy [31]. Therefore 
NF-κB signaling was early identified as a potential target 
for cancer therapy [32,33]. Moreover, almost 20 years ago 
NF-kB was described as a key BCR-ABL partner [34–36]. 
Since then, various reports have further investigated the 
contribution of different NF-κB components in CML 
and Ph+ ALL pathogenesis. These results have allowed 
a better understanding of NF-κB signaling and have 
drawn particular attention on its targeting in Ph+ leukemia 
context. In this review, we will consider the BCR-ABL/
NF-κB crosstalk with relation to the development and 
maintenance of leukemia and we will debate the potential 
therapeutic strategies to block NF-κB signaling in Ph+ 
malignancies.
NF-kB signaling
The Nuclear Factor-kappaB (NF-κB) family of 
transcription factors mediates various biological processes 
which can be deregulated in cancer pathogenesis and 
involved in generating resistance to chemotherapy. 
Consequently, the experimental dissection of the NF-κB 
signaling network offers new opportunities to exploit 
therapeutically the inhibition of the pathway [27, 37–
41]. NF-κB members comprise two protein subfamilies 
which are synthesized as large precursors, namely Rel 
and NF-κB. In turn, the Rel family includes RelA (also 
known as p65), RelB and c-Rel, while NF-κB members 
are p50 (that originates from the p105 precursor) and p52 
(that originates from the p100 precursor). They are also 
called NF-κB1 and NF-κB2 respectively and are able to 
form hetero- and homo-dimers. The NF-κB pathway is 
modulated by negative or positive regulatory elements 
associated with canonical and non-canonical pathways 
(Figure 1). The canonical pathway is based on the 
negative regulation of IκB-α [42, 43], which retains p65/
p50 heterodimers in the cytoplasm in a latent state, thus 
inhibiting their binding to DNA. Various stimulations 
such as cytokines, growth factors, LPS and other stimuli, 
promote the activation of the IKK kinase complex, 
which in turn phosphorylates IκB-α on serine residues 
[44–46]. This event primes IκB-α to ubiquitination and 
its consequent degradation through the proteasome. Upon 
IκB-α degradation, p65/p50 complex translocates into the 
nucleus where it binds to the enhancer or promoter regions 
of specific DNA sequences and promotes transcription of 
target genes. NFKBIA, the gene encoding for IκB-α, is one 
of the first genes to be induced, providing a mechanism of 
negative feedback [47, 48]. The non-canonical pathway 
relies on the p50 and p52 subunits, as reviewed elsewhere 
[49,50]. In particular, the kinase NIK (NF-κB inducing 
Kinase) is able to activate IKK-α complex which mediates 
p100 phosphorylation. This results in the proteasome-
dependent processing of p100 to p52, driving activation 
of RelB/p52 heterodimers that in turn target distinct κB 
elements on DNA[51]. NF-κB is known to regulate several 
cellular processes, including proliferation [28], protection 
from apoptosis [29, 30, 52], cell cycle [53], cell migration 
and angiogenesis [54] and resistance to chemotherapy[31]. 
Due to this broad spectrum of effects, deregulation of 
NF-κB signaling has been strongly associated with the 
development of several diseases, including hematological 
cancers [55–57]; however, NF-κB  family members 
mutations, which induce its constitutive activation, are 
rare events in hematological malignances [55]. It is clear 
that the two pathways of NF-kB differ in their signaling 
mechanisms. Moreover, increasing evidence suggests that 
the non-canonical pathway regulates important biological 
functions in the lymphoid compartment, such as lymph 
node organogenesis, B-cell development and survival 
and it is also found deregulated mostly in lymphoid 
malignancies [58]. In addition, it should be noted that the 
activation of NF-κB is in most cases a consequence of 
several other aberrantly activated pathways (for example 
EGF-R [59], HGF/c-MET [60], oncogenic Ras [61, 62], 
PI3K [63], AKT [64], SRC [65] and others). 
HISTORICAL PERSPECTIVE ON BCR-
ABL/NF-ΚB RELATIONSHIP
Cell lines and cellular models
The first observations that Bcr-Abl regulates 
the NF-κB signaling were made with the p210-Bcr-
Abl-transformed DA1, an IL-3-dependent murine cell 
line [34]. In this cellular model, Bcr-Abl expression 
abrogated IL-3-dependent growth and enabled NF-
κB to bind to DNA-responsive elements. Notably, the 
inhibition of RelA by antisense oligonuclotides reverted 
the IL-3-independence of Bcr-Abl-transformed DA1 
cells, suggesting that NF-κB may contribute to Bcr-Abl-
mediated tumorigenesis. Similar conclusions were drawn 
using the Bcr-Abl-expressing 32D cell line [35], an Il-3 
dependent murine myeloblast-like cell line, where Reuther 
and colleagues further dissected the mechanisms of NF-
κB activation by Bcr-Abl showing that Ras is required for 
the regulation of NF-κB. In particular, RasA17 mutant, 
acting as a dominant negative protein, affects the ability 
of BCR-ABL to activate NF-κB. Notably, expression of 
an IκB-α isoform unable to be degraded, prevented NF-
κB activation by Bcr-Abl. Thus, in the specific context of 
Bcr-Abl-dependent cells, NF-κB appeared unnecessary 
to protect cells from death caused by IL-3 removal or 
treatment with DNA damage agents. However, a murine 
xenotransplantation model of Bcr-Abl-32D cells showed 
that NF-κB activation was necessary to mediate Bcr-Abl 
tumorigenesis, suggesting that in vitro cellular models 
may harbor mechanistic bias for the study of NF-κB 
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signaling [35]. Other groups have subsequently confirmed 
the Bcr-Abl/NF-κB connection [66] in vitro. Using a 
Bcr-Abl-BaF3 cell line, a Il-3 dependent murine pro B 
cell line, it was shown that NF-κB activation is partially 
dependent by IκB-α degradation but independent of IκB 
kinase (IKK) activity [36], while Ras appeared necessary 
for the activation of NF-κB. This work described for the 
first time NF-κB activation in primary CML blast crisis 
[36]. In addition to the essential role of Ras, it was also 
demonstrated that various and complex mechanisms were 
responsible for triggering NF-κB activity. In particular, 
NF-κB activation is also dependent on downstream targets 
of Bcr-Abl including MEK kinase-1 (MEKK1). Bcr-Abl 
enhances MEKK1 expression and kinase activity which in 
turn strongly induces NF-κB signaling. On the contrary, 
inhibition of MEKK1 with a dominant-negative mutant 
decreased NF-κB activation [67]. Bcr-Abl can induce 
activation of the NF-κB pathway in Bcr-Abl cells by 
Protein Kinase D2 (PKD2). It has been established that 
Bcr-Abl induces activation of NF-κB in LAMA84 cells, 
a human CML blast crisis cell line, through tyrosine 
phosphorylation of PKD2 [68] at Tyr438. Among the 
mechanisms by which NF-κB can be activated by Bcr-
Abl it is worth mentioning that osteopontin -a protein 
produced and secreted by Bcr-Abl-expressing cells- can 
bind integrin receptors and regulate IκB-α expression in 
an autocrine manner [69]. Finally, by analyzing NF-κB 
network activity, it was pointed out a negative association 
between the expression of CUEDC2, which is associated 
with endocrine resistance in breast cancer, and NF-κB 
signaling. In particular knockdown of CUEDC2 in K562 
cell line, a CML blast crisis cell line, causes an  increase 
of IKK complex phosphorylation and favors IκB-α 
degradation [70]. Altogether, these original contributions 
clearly suggest that: i) BCR-ABL is able to promote NF-
κB activation in vitro; ii) Ras is necessary for NF-kB 
activation; iii) the contribution of IκB-α and IKK in the 
regulation of NF-κB is not entirely clear -at least in cell 
lines- and needs further studies in murine models (Figure 
2). 
Figure 1: NF-κB pathway. Canonical and non-canonical NF-κB pathways are represented in the left and in the right of the figure 
respectively. The activation of canonical pathway is mediated by various ligands such as Tumor Necrosis Factor (TNFα), Interleukin-1 
(IL-1), or growth factors. The activation relies on the phosphorylation of IκB-α by the IKK complex and subsequent its degradation by 
the proteasome. Consequently, the RelA/p50 complex translocates to the nucleus where it activates the transcription of target genes. The 
non-canonical pathway is based on the activation of IKKα by the NF-κB-inducing kinase (NIK), after stimulation. In turn the complex NIK-
IKKα phosphorylates the p100 subunit. As a consequence, p100 is processed in a proteasome dependent manner, generating the subunit 
p52. This event results in the activation of p52-RelB that induces the transcription of distinct target genes.
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Primary Philadelphia positive samples
In human-derived primary Ph+ leukemias 
the assessment of NF-κB activation led to different 
conclusions. In an original report based on electrophoretic 
mobility shift assay (EMSA) analysis, NF-κB was found 
highly active in CML blast crisis [36]. Similarly, other 
analyses with a group of myeloid neoplasms, including 
AML, chronic phase CML and blast phase CML, described 
that NF-κB is markedly active in CML blast crisis 
when compared to the chronic phase of the disease[71]. 
However, successive works which adopted different 
experimental approaches to measure NF-κB activity, 
showed that even the chronic phase of CML is associated 
with an increased NF-κB activation [72] when compared 
to normal bone marrow samples, suggesting a functional 
heterogeneity. Conversely, in Ph+ ALL, constitutive NF-
κB activation may be considered a common feature of 
the disease [73]. As a general principle, NF-κB is more 
active in Ph+ ALL and CML blast crisis with respect to 
the chronic phase disease. Apparent discrepancies among 
different reports could be explained either accordingly 
to different sensitivity of the methods used or related to 
population heterogeneity. Undoubtedly, the data available 
so far highlight the relevant role of NF-κB (regulation) in 
Ph+ leukemias. 
Murine models
Besides cell lines, murine models supply a 
good platform for studying the role of NF-κB in the 
pathogenesis and development of leukemias [74, 75]. 
Van Etten and colleagues showed in mouse models of 
CML and Ph+ B-ALL that NF-κB contributes to myeloid 
and lymphoid leukemogenesis through Bcr-Abl [76]. 
Primary bone marrow murine hematopoietic cells were 
infected to express both BCR-ABL and an IκB-α mutant 
(IκBαSR) that stabilizes NF-κB complex in the cytosol 
or dominant-negative, kinase-inactive, mutants of IKK 
[76]. Infections were performed to recapitulate Ph+ ALL 
and CML-like phenotypes. In these models, IκBαSR and 
IKK mutants were shown to attenuate Bcr-Abl-mediated 
leukemogenesis and to prolong survival. Notably, authors 
demonstrated that NF-kB inhibition affects BCR-ABL 
leukemogenesis partially through the impairment of 
leukemic stem cells. Specifically, IκBαSR and IKK 
Figure 2: BCR-ABL/NF-κB crosstalk. Numerous pathways, including Ras, MEKK1, c-Jun N-terminal kinase (JNK) and protein 
kinase D2 (PKD2) are activated by the Bcr-Abl and converge on NF-κB activation. NF-κB activation is also under the regulation of 
osteopontin or CUEDC2, as indicated.
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mutants decrease the number of leukemia stem cells 
capable of initiating tumorigenesis [76]. Furthermore, 
using limiting dilution secondary transplantation of BM 
from CML mice, authors clearly demonstrated that SR-
IkBα and IKKα mutant significantly affect the number 
of cells that are able to recapitulate the disease in the 
secondary recipient. Beside demonstrating that IkBα 
and IKK are essential components of the BCR-ABL 
leukemogenesis, this work also demonstrated that SRIkBα 
and IKK mutants significantly increase the sensitivity of 
Ph+ cells to TKI. This work provided the first evidence 
that in vivo Bcr-Abl activates NF-κB through the classical 
(canonical) IKK/IκB-α pathway and strongly supports 
the rationale that therapies designed to target canonical 
NF-κB network may be effective in Ph+ leukemias. 
Furthermore, this preclinical in vivo model rules out most 
of the controversial results obtained with cellular models, 
and  offers the chance to design clinical trials with IKK 
inhibitors in combination with TKI in highly challenging 
settings, such as the therapy of Ph+ ALL and CML blast 
crisis.  
The contribution of the microenvironment 
NF-κB signaling is also under the control of several 
cytokines produced by stromal cells or by the tumor itself 
[42]. The Tumor Necrosis Factor-α (TNF-α) is one of the 
most important cytokines able to activate NF-κB [77]. At 
the same time, TNF-α signaling was shown to be affected 
by Bcr-Abl [78]. In particular, ectopic expression of BCR-
ABL promoted TNF-α receptor down-regulation with 
consequent impairment of TNF-α signaling. Recently, 
it was demonstrated that CML stem/progenitor cells 
secrete TNF-α in a Bcr-Abl Kinase-independent manner 
[79] promoting NF-κB activation. Specifically, autocrine 
TNF-α production is able to sustain CML stem cells and 
progenitor cells survival and pharmacological targeting 
of the TNF-α/NF-κB pathway is able to synergize with 
Bcr-Abl inhibition to a relevant degree. Again, these 
observations point to a key role of the microenvironment in 
the regulation of NF-κB signaling in CML [79]. Similarly 
to TNF-α, the TGF-β signaling was also shown to play an 
essential role in CML biology [80–82]. Notably, TGF-β 
orchestrates CML cellular destiny through a complex 
PI3K/AKT/NF-κB/MMP9 pathway, which includes 
NF-κB [83]. Overall, these data suggest that NF-κB is 
regulated by the microenvironment where Ph+ positive 
cells reside. In particular, both autocrine TNF-α secretion 
and cytokines produced from the environment are able to 
sustain NF-κB signaling in CML cells. The presence of a 
Bcr-Abl independent mechanism of NF-κB activation in 
Ph+ leukemias has two important implications. Firstly, it 
suggests that non-cell autonomous or micro-environmental 
Figure 3: NF-κB is regulated by the environment where Ph+ positive cells reside. Interactions between Ph+ stem/progenitor 
cells and stromal cells and representation of TGF-β and TNF-α networks. Both TGF-β and TNF-α can be secreted by CML cells as part of 
a autocrine/paracrine loop able to sustain NF-kB signaling. Moreover, Ph+ CML cells can be regulated by TGF-β and TNF-α produced by 
stromal cells or inflammatory cells. This mechanism may promote NF-kB signaling in a BCR-ABL-independent manner. 
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processes are important in the maintenance of leukemias 
and therefore must be considered to design an effective 
targeted therapy for these cancers. Secondarily, the 
contribution of the stroma in the activation of NF-κB may 
also explain most of the controversial results observed 
in cell lines vs primary samples vs murine models. For 
instance, IKK and IκB- α appeared dispensable for NF-
κB activation in some cell line models, while are clearly 
important in murine models or in primary cells. These 
discrepancies may be explained by the absence of the 
microenvironment, a source of TNF-α and TGF-β , in cell 
line experiments (Figure 3).
THERAPEUTICAL IMPLICATIONS
The important role of NF-κB in tumor cells and 
through the influence of the microenvironment suggests 
that this pathway can be therapeutically exploited for 
the treatment of Ph+ leukemias. Several small molecules 
inhibitors have been developed to target NF-κB-sustained 
cancers [84] and many of them have been tested in the 
context of Ph+ leukemias (Figure 4). The first observations 
of the efficacy of NF-κB targeting strategies come from 
CML and Ph+ ALL cellular models and were obtained with 
BAY11-67082, an inhibitor of the IκB-α phosphorylation 
[66], and Bortezomib (PS-341), which blocks proteasome-
mediated IκB-α degradation [85–87]. Notably, the 
potential usage of Bortezomib in NF-κB-dependent 
contexts should have high priority in the design of early 
clinical trials due to its availability for in-human use and 
previous acquired clinical experience. NF-κB inhibitors 
appear promising also in combination with other agents, in 
particular in combination with tyrosine kinase inhibitors. 
IκB-α degradation inhibition with Bortezomib synergizes 
with the pro-apoptotic effects of Imatinib, when the two 
drugs are administered sequentially [88], suggesting that 
this strategy could be used in those patients who exhibit 
a partial response to TKI. It was also shown that the IKK 
Figure 4: Targeting the NF-κB pathway. This Figure reports those drugs that have been shown to modulate NF-κB in Ph+ leukemias. 
In particular, NF-κB signaling can be modulated by IKK inhibitors (such as PS1145, BAY11-67082, AS602868), proteasome inhibitors 
(Bortezomid) or with drugs able to act at the transcriptional level (alantolactone, parthenolide).
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inhibitors PS-1145 [72] and AS602868 [89] are able to 
promote CML primary cells apoptosis. In particular 
AS602868 presents an increased efficacy in BCR-ABL-
T315I mutated cells [89]. In this specific cases, only 
Ponatinib is active against mutated Bcr-Abl kinase, 
although with a significant risk of major side effects 
[90]. Therefore, IKK inhibitors could be effective for the 
treatment of this specific mutation. Other compounds able 
to selectively target and inhibit NF-κB pathway have been 
described to be effective in Ph+ leukemias. In particular, 
Parthenolide has been shown to promote apoptosis of 
CML blast crisis cells [91], while Resveratrol [92], 
Xanthohumol [93], Curcumin [94], Alantolactone [95] 
were shown to be effective in other CML cell lines. Lastly, 
it is known that NF-κB is able to promote resistance to 
chemotherapeutic agents. Conventional chemotherapy 
is still necessary for the treatment of Ph+ ALL and CML 
blast crisis, due to reduced efficacy of TKI in these 
clinical scenarios. In line with these considerations, it was 
demonstrated that NF-κB inhibition restores sensitivity 
to Etoposide, a chemotherapeutic agent [92]. Overall, we 
can assert that NF-κB signaling may be therapeutically 
attackable, offering the chance to achieve synthetic 
lethality with TKIs and to respond -at least in part- to the 
unmet clinical need in the field of Ph+ leukemias. 
NEW TUMOR SUPPRESSIVE 
PERSPECTIVES: THE IΚB-α/P53 
CONNECTION
We have recently investigated the contribution 
of IκB-α in CML signaling [96]. IκB-α was generally 
described as a tumor suppressor and found deleted in about 
20% of glioblastomas [97] and mutated in some cases of 
Hodgkin diseases [98]. In the attempt to observe IκB-α 
under-expression/abnormal localization in CML, we ended 
up to highlight a sustained IκB-α expression in CML 
primary samples [96]. Notably, we also observed that 
IκB-α is able to promote p53 nuclear exclusion in CML 
cells. IκB-α was previously reported to bind to both NF-κB 
and p53 [99–101]. Our data translated these observations 
in the setting of CML, describing a novel Bcr-Abl/IκB-α/
p53 network, with potentially relevant implications for 
both tumorigenesis and therapy. In particular, Bcr-Abl/
IκB-α complex promotes the nuclear exclusion and 
consequent inactivation of p53 [96], an essential tumor 
suppressor [102]. IκB-α can indeed be responsible for 
both the regulation of NF-κB and the triggering of p53 
functional inactivation. Very recently, it was clearly 
demonstrated that CML CD34+ cells are characterized by 
the down-modulation of p53 targets and that drugs able 
to enhance p53 levels, together with c-MYC targeting 
drugs, promote CML cells selective apoptosis induction 
[103]. Indeed, the mechanisms of p53 modulation in CML 
pathogenesis appeared to be highly complex and, as a 
consequence, the development of strategies to reactivate 
p53 in CML and the effects of drugs that modulate IκB-α 
degradation (proteasome inhibitors) on p53 require further 
experimental investigations but may represent a new 
challenging approach to cure Ph+ leukemias.
DISCUSSION
The NF-κB signal transduction is a very complex 
and stratified network, involving both canonical and 
non-canonical pathways and an integrated system of 
regulators. It plays an essential role in the pathogenesis of 
several cancers and offers several chances of therapeutic 
intervention with clinically available drugs. Almost 
20 years ago, NF-κB was shown to play an essential 
role in the pathogenesis (and treatment) of Ph+ positive 
leukemias. While few controversial results have been 
reported in different cellular models and primary Ph+ 
samples, the following conclusions can be summarized. 
1) NF-κB is aberrantly activated in Ph+ leukemias and in 
particular in CML blast phase and Ph+ ALL. The basal 
level of NF-kB activation in CML chronic phase is 
difficult to define accordingly to the methods of detection, 
samples management and appropriate controls. 2) Both 
Bcr-Abl signaling and non-cell autonomous regulation 
by cytokines, such as TNF-α and TGF-beta, cooperate 
to promote NF-κB activation in Ph+ leukemia. The 
existence of these two  mechanisms of NF-κB activation 
may explain the differences observed in various Ph+ cell 
lines and primary cells: the removal of cells from the 
bone marrow environment could indeed affect the stromal 
contribution to NF-κB signaling. 3) In accordance to the 
previous point, murine modeling of NF-κB signaling 
in CML clearly demonstrates that IKK and IκB-α are 
mandatory to promote BCR-ABL tumorigenesis, ruling 
out the controversial results obtained in cell lines. 4) As 
observed in murine models, targeting IKK or preventing 
IkB-α degradation with proteasome inhibitors appear the 
best therapeutic interventions to inhibit NF-kB in Ph+ 
leukemias. Following the impressive results with the in 
vivo preclinical murine model, the association with TKI 
and IKK inhibitors should be tested with appropriate 
clinical trials to treat challenging Ph+ leukemias, such as 
CML blast crisis and Ph+ ALL. 5) Beside being a key NF-
κB signaling inhibitor, IκB-α plays also an essential role 
in the regulation of p53 cellular compartmentalization and 
function, as we recently pointed out [96]. In particular, 
IκB-α acts at the crossroad between oncogenic signal 
(toward NF-κB) and tumor suppressive signal (toward 
p53). 6) The NF-IκB pathway may also be attractive 
for its ability to modulate p53 activity, even if further 
experimental approaches are mandatory to investigate this 
challenging therapeutic opportunity in the treatment of 
Ph+ leukemias.
As time has gone, during these 20 years the CML/
NF-κB relationship has become more mature and has 
offered different chances to investigate the contribution of 
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this pathway in tumorigenesis and cancer therapy. 
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